SARS-CoV-2 Spike Protein S1 Receptor-Binding Domain (S1RBD)
Origin:
Recombinant
Cat No.:
41A221
Source:
E.coli
Size:
0.1 mg
Tag:
No Tag
Purity:
>95%
Antigenicity Test
Antigenicity validated in patient serum samples via ELISA test by coating SARS-CoV-2 S1RBD as capture antigen.
Antiginetic response even in 900-fold diluted patient serum.
Amino Acid Sequence
NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATV
INTRODUCTION
Since December 2019, outbreak of SARS-CoV-2 infection has become a major epidemic threat in China and brought back the attention of pathogenic coronavirus to the spotlight. Spike protein is an envelope-anchored protein that mediates the recognition and binding of SARS-CoV-2 to host cells. S1 can be further cleaved by the host protease into two subunits called S1 and S2, wherein the S1 polypeptide contain a receptor binding domain (RBD) crucial for the specific recognition and interaction with human receptor ACE2, which is the first and the most essential step for the virus infection.
Expressed in E.coli with total 194 AA. Mw: 21.8 KDa (calculated).
Recombinant antigen for research use or manufacturing only.
DATA SHEET
AMINO ACID SEQUENCE
NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATV
Antigenicity Test
Antigenicity validated in patient serum samples via ELISA test by coating COVID-19 S1RBD as capture antigen.
Antiginetic response even in 900-fold diluted patient serum.
QUALITY CONTROL TEST
BCA to determine quantity of the protein.
SDS PAGE to determine purity of the protein.
FORMULATION
As liquid with vials containing S1RBD to 1.8 mg/mL in 50mM Tris, 300mM NaCl, 10% Glycerol, PH8.0.